A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alexander Spira, MD, PhD
Virginia Cancer Specialists Research Institute
Principal InvestigatorKOL profile → - Hidehito Horinouchi, MD, PhD
National Cancer Center Hospital
Principal Investigator - Jinming Yu, MD, PhD
Shandong Cancer Hospital and Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
264 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Brussels, Belgium
Recruiting - Research Site
Edegem, Belgium
Recruiting - Research Site
Haine-Saint-Paul, Belgium
Recruiting - Research Site
Leuven, Belgium
Recruiting - Research Site
Liège, Belgium
Recruiting - Research Site
Sint-Niklaas, Belgium
Recruiting
- Research Site
Barretos, Brazil
Active, not recruiting - Research Site
Londrina, Brazil
Active, not recruiting - Research Site
Porto Alegre, Brazil
Active, not recruiting - Research Site
Porto Velho, Brazil
Active, not recruiting - Research Site
Rio de Janeiro, Brazil
Active, not recruiting - Research Site
Santo André, Brazil
Active, not recruiting - Research Site
São Paulo, Brazil
Active, not recruiting - Research Site
São Paulo, Brazil
Withdrawn - Research Site
São Paulo, Brazil
Withdrawn - Research Site
São Paulo, Brazil
Withdrawn - Research Site
Taubaté, Brazil
Active, not recruiting
- Research Site
Calgary, Alberta, Canada
Recruiting - Research Site
Kelowna, British Columbia, Canada
Recruiting - Research Site
Laval, Quebec, Canada
Recruiting - Research Site
Montreal, Quebec, Canada
Recruiting
- Research Site
Las Condes, Chile
Recruiting - Research Site
Port Montt, Chile
Recruiting - Research Site
Santiago, Chile
Recruiting - Research Site
Santiago, Chile
Recruiting - Research Site
Santiago, Chile
Recruiting - Research Site
Santiago, Chile
Recruiting - Research Site
Temuco, Chile
Recruiting
- Research Site
Aix-en-Provence, France
Recruiting - Research Site
Angers, France
Recruiting - Research Site
Bobigny, France
Recruiting - Research Site
Clermont-Ferrand, France
Withdrawn - Research Site
Lille, France
Recruiting - Research Site
Paris, France
Recruiting - Research Site
Pau, France
Recruiting - Research Site
Quimper, France
Recruiting - Research Site
Saint-Grégoire, France
Recruiting - Research Site
Saint-Quentin, France
Recruiting - Research Site
Vantoux, France
Recruiting - Research Site
Villeurbanne, France
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Feb 2022
- Primary completion
- 12 Jul 2028
- Completion
- 1 Oct 2030
- Last update posted
- 10 Jun 2026
- Registered enrollment
- 860
- Registry id
- NCT05211895
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.